Gene therapies for Ocular diseases

THE PROBLEM

Until recently the scientific community accepted aging as something natural and inevitable, but now it is seen as a master disease that is treatable, can be slowed, even reversed.
This transformative perspective has ignited a new era of research and innovation, leading to remarkable breakthroughs in combating the effects of aging.

the solution

We now possess a much better understanding of the pathophysiology of age-related eye conditions, and it is evident that the root cause is genetic. Equipped with new gene therapy techniques, we have the potential to not only significantly slow down the progression of ocular diseases but also facilitate their reversal, including the regeneration of the optic nerve.

our first target : glaucoma

Glaucoma is the leading cause of irreversible blindness worldwide.
We are currently developing a groundbreaking approach that utilizes gene therapy to regenerate the damaged optic nerve while at the same time providing neuroprotection.
This discovery represents a potential cure for glaucoma that has the ability to restore patients' lost vision, something previously considered impossible.

There If you have already experienced visual field loss, traditional glaucoma treatments cannot restore those lost areas. You will likely be prescribed daily eye drops aimed at lowering intraocular pressure (IOP) to slow down the progression of the disease. Unfortunately, this may be a lifelong regimen. However, one potential avenue for regaining lost vision is through nerve regenerative gene therapy offered by GENORASIS.

Possibly, but in this case, gene therapy presents certain disadvantages when compared to traditional methods of IOP reduction such as eye drops or valve implants. If the target IOP isn't achieved while using eye drops, the doctor can make adjustments to the dosage, prescribe an alternative drug, or add one or more drugs as needed. This flexibility doesn't seem feasible with gene therapy, potentially requiring additional interventions. However, it's important to note that while this approach can slow down the progression of glaucoma, it does not offer nerve regeneration or restoration of lost vision.

the crystalline lens

Targeting the crystalline lens with gene therapy to avoid alterations in its structure, morphology and function that leads initially to the diminished ability to focus in different distances (presbyopia) and later to opacification that severely impairs visual acuity and the perception of images and colors (cataract).

THE RETINA AND THE OPTIC NERVE

Targeting the retina and especially the macula to prevent Age-Related Macular Degeneration and Diabetic Retinopathy, but also to improve color perception and visual acuity.
Targeting the diseases and conditions that cause the deterioration and loss of nerve fibers in the optic nerve, including glaucoma, optic neuritis, injuries, and the inevitable loss from aging.